Evrópusambandið - íslenska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxólaner - ectoparasiticides til almennrar notkunar - hundar - meðferð fló (ctenocephalides sus og c. canis) sníkjudýra. varan er hægt að nota sem hluti af meðferðaráætlun til að stjórna lungnæmisbólgu (fad). meðferð merkið (dermacentor reticulatus, ixodes ricinus, rhipicephalus sanguineus) sníkjudýra. meðferð demodicosis (af völdum demodex canis). meðferð sarcoptic girl (af völdum sarcoptes scabiei var. canis).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 og 5.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

retrophin europe ltd - cholic sýru - umbrot, innfæddir villur - galla og lifrarmeðferð - cholic sýru fgk er ætlað fyrir meðferð meðfæddan villur af aðal galli sýru myndun, í ungabörn frá einum mánuði aldri fyrir samfelld ævilangt meðferð í gegnum fullorðinsár, tekur eftir einn ensím galla:steról 27-hýdroxýlkljúfs (kynna eins og cerebrotendinous xanthomatosis, ctx) skort;2- (eða alfa-) methylacyl-str racemase (amacr) skort;kólesteról 7 alfa-hýdroxýlkljúfs (cyp7a1) skort.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

dynavax gmbh - lifrarbólga b yfirborðs mótefnavaka - lifrarbólga b - bóluefni - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vbi vaccines b.v. - lifrarbólga b yfirborðs mótefnavaka - lifrarbólga b - bóluefni - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - natríum ertapenem - bakteríusýkingar - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 og 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - atomoxetinum hýdróklóríð - hart hylki - 60 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - atomoxetinum hýdróklóríð - hart hylki - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - atomoxetinum hýdróklóríð - hart hylki - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - atomoxetinum hýdróklóríð - hart hylki - 18 mg